Solve Therapeutics

About Solve Therapeutics

Solve Therapeutics is focused on developing novel antibody-drug conjugates (ADCs) with high selectivity and optimized payload delivery for targeting cancer, utilizing their proprietary hydrophilic linker system, CloakLink™, to improve therapeutic outcomes for patients.

Products & Services

SLV-154:An ADC in Phase 1 clinical development targeting distinct membrane receptor proteins on solid tumors, featuring a highly selective antibody, CloakLink™ linker, and potent cytotoxic payload.

ADC 3:An ADC in development targeting solid tumors, with details on clinical phase not specified.

CloakLink™:A proprietary hydrophilic and stable linker system designed to enhance plasma stability, improve pharmacokinetics, reduce toxicity, and enable potent tumor cell killing in ADCs.

Specialties

Antibody-Drug Conjugates (ADCs) Oncology Drug Development Precision Engineering Hydrophilic Linker Systems (CloakLink™) Theragnostics Solid Tumor Targeting

Funding History

Debug: View Raw Funding Data

#	Type	Amount Fields	Date Fields	Investors
1	RT: Equity Financing T: - FT: Equity Financing	A: 120000000 MR: - FA: $120 million FAN: 120000000	D: 2025-11-17 FD: 2025-11-17	12 investors

Equity Financing Latest

2025-11-17

$120.0M

12 investors (Pro only)

Growth Metrics

+45%

Employee Growth

YoY

3.2x

Funding Growth

Last Round

12

Markets

Operating

10K+

Customers

Active

View 3 more growth metrics with Pro

Unlock All Metrics

Mock Up

Team & Leadership

K

Katti Jessen

SVP, Translational Sciences

D

Dave Johnson

CEO, Solve Therapeutics

C

Clayton Knox

President

Y

Yakov N. Kogan

SVP, Operations & Alliances

B

Brian Lannutti

EVP, Research

L

Langdon Miller

EVP, Development and Chief Medical Officer

View 12 more team members with Pro

Unlock Full Team Directory

Recent News